Tabula Rasa HealthCare Inc Investor Q&A to Discuss AJMC Publications Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst : Okay. Can you hear me now?

Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst : Okay, great. Maybe just starting off, along the lines of Kevin, what you were just talking about, maybe if you could just kind of help us understand what you think these studies mean in context of your current sales pipeline. You talked about the significant growth you've been able to generate there. Is the absence of this type of data, what you think was holding up a lot of those decisions and now we should see the ice break and the pace of conversion kind of pipeline and the bookings and revenue quicken or maybe just kind of help us frame out what the near-term kind of commercial impact of these studies are? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 28, 2021 / 3:00PM, TRHC.OQ - Tabula Rasa HealthCare Inc Investor Q&A to Discuss AJMC Publications

Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst : Okay. And then the data and the studies begins in 2018, but I think you had a pretty good year in 2017 as far as driving savings in the EMTM pilot. Just curious why the 2017 data wasn't included in your performance calculation? Jacques Turgeon - Tabula Rasa HealthCare, Inc. - Chief Scientific Officer & CEO of TRHC Precision Pharmacotherapy, Research and Development Institute Yes. I guess I can take this one. Yes. I mean, the 2017 was the first year of the program. So we had a lower number of patients enrolled in this year for a full year. And as we wanted to do a difference and difference analysis so using the same patient as their own control to see how they were evolving year-to-year. We just -- we looked at the 2018 and 2018-2019 data, which were allowing us to have more people that have received medication review -- safety review. So that's the reason we use this data, even though, overall, the data for the 2017 have shown the same time of site savings for -- when we're looking at overall medical expenditures.